Soros Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Soros Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,295	Closed	-$1.96M	–	247
2025 Q3	$1.96M	Buy	+4,295	New	+$1.75M	0.03%	167
2025 Q2	–	Sell	-60,000	Closed	-$16.2M	–	209
2025 Q1	$16.2M	Buy	+60,000	New	+$15.4M	0.24%	106
2019 Q3	–	Sell	-40,000	Closed	-$2.9M	–	176
2019 Q2	$2.9M	Buy	+40,000	New	+$3.07M	0.07%	116
2017 Q3	–	Sell	-7,000	Closed	-$558K	–	231
2017 Q2	$558K	Buy	+7,000	New	+$447K	0.01%	125
2016 Q1	–	Sell	-6,000	Closed	-$565K	–	233
2015 Q4	$565K	Buy	+6,000	New	+$556K	0.01%	180
2014 Q2	–	Sell	-3,092	Closed	-$208K	–	366
2014 Q1	$208K	Buy	+3,092	New	+$239K	﹤0.01%	302

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Soros Fund Management's ALNY Position: Q4 2025 in Review

Soros Fund Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,295 shares — an estimated $1.96M sold.

Soros Fund Management first reported a position in ALNY in Q1 2014 and held it in 6 quarters. The position peaked at $16.2M in Q1 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Soros Fund Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Soros Fund Management sold 4,295 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $1.96M.
Soros Fund Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Soros Fund Management's Alnylam Pharmaceuticals position peaked at $16.2M in Q1 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Soros Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.